Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 3, 2025

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase 3 VALIANT study investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.

GlobeNewsWire • Dec 3, 2025

Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 2, 2025

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Citi's 2025 Global Healthcare Conference Date/Time: Tuesday, December 2, 2025 at 2:30 p.m.

GlobeNewsWire • Nov 25, 2025

Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript

Apellis Pharmaceuticals, Inc. ( APLS ) Stifel 2025 Healthcare Conference November 12, 2025 2:40 PM EST Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Executive Vice President of Commercial Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Annabel Samimy Stifel, Nicolaus & Company, Incorporated, Research Division Good afternoon, everyone, and welcome to the Apellis session. It's our pleasure to have CFO, Tim Sullivan; and Chief Commercial Officer, David Acheson, with us today.

Seeking Alpha • Nov 12, 2025

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

GlobeNewsWire • Nov 12, 2025

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET.

GlobeNewsWire • Nov 5, 2025

Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates

APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.

Zacks Investment Research • Oct 31, 2025

Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. ( APLS ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Eva Stroynowski Cedric Francois - Co-Founder, President, CEO & Director David Acheson - Executive Vice President of Commercial Caroline Baumal - Chief Medical Officer Timothy Sullivan - CFO & Treasurer Conference Call Participants Jonathan Miller - Evercore ISI Institutional Equities, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Ellen Horste Lachlan Hanbury-Brown - William Blair & Company L.L.C.

Seeking Alpha • Oct 31, 2025

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.

GlobeNewsWire • Oct 30, 2025